1. Scrip
  2. >>Archive

Interview: Cipla's heiress on taking the legacy forward & the firm's new baby

 
• By Anju Ghangurde

There's probably a lot riding on her but Samina Vaziralli, part of Cipla's founding family and new inductee on the company's board, appears unfazed by the task on hand or all the speculation around top level exits at the firm.

There's probably a lot riding on her but Samina Vaziralli, part of Cipla's founding family and new inductee on the company's board, appears unfazed by the task on hand or all the speculation around top level exits at the firm.

Ms Vaziralli is the daughter of Cipla's vice chair M K Hamied, who is the brother

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’